Wide Ranks

BLTE

Belite Bio, Inc

67.44

Top Statistics
Market Cap 2 B Forward PE -67.44 Revenue Growth 0.00 %
Current Ratio 30.73 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash Total Cash Per Share Total Debt
Total Debt To Equity Current Ratio 30.73 Book Value Per Share 3.66
All Measures
Short Ratio 248.00 % Message Board Id finmb_1776217412 Shares Short Prior Month 270587
Return On Equity -0.4004 City San Diego Uuid 8f0c212f-6730-31e5-bde8-f751aab9807d
Previous Close 64.02 First Trade Date Epoch Utc 1 B Book Value 3.66
Volume 86161 Price To Book 18.45 Fifty Two Week Low 31.00
Shares Short Previous Month Date 1 B Target Median Price 78.50 Max Age 86400
Recommendation Mean 1.40 Sand P52 Week Change 0.3133 Target Mean Price 79.25
Net Income To Common -33034000 Short Percent Of Float 0.0186 Implied Shares Outstanding 30 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 93960
Average Volume10days 93960 Next Fiscal Year End 1 B Held Percent Insiders 0.5860
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 64.02 Target Low Price 50.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 63.77 Open 63.00 Dividend Yield 0.00 %
State CA Return On Assets -0.2558 Time Zone Short Name EST
Trailing Eps -1.10 Day Low 62.53 Address1 12750 High Bluff Drive
Shares Outstanding 30 M Price Hint 2 Target High Price 110.00
Website https://www.belitebio.com 52 Week Change 0.6030 Average Volume 66259
Forward Eps -0.9600 Recommendation Key strong_buy Is_sp_500 False
Regular Market Day High 70.00 Profit Margins 0.00 % Fifty Two Week High 86.53
Day High 70.00 Shares Short 241075 Regular Market Open 63.00
Industry Key biotechnology Earnings Growth 0.00 % Revenue Growth 0.00 %
Shares Percent Shares Out 0.0078 Currency USD Time Zone Full Name America/New_York
Market Cap 2 B Is_nasdaq_100 False Zip 92130
Quote Type EQUITY Industry Biotechnology Long Name Belite Bio, Inc
Regular Market Day Low 62.53 Held Percent Institutions 0.0049 Current Price 67.44
Address2 Suite 475 Financial Currency USD Current Ratio 30.73
Industry Disp Biotechnology Number Of Analyst Opinions 4 Country United States
Float Shares 12 M Two Hundred Day Average 50.07 Forward PE -67.44
Regular Market Volume 86161 Ebitda -35298752 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States.

The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.

It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes.

Belite Bio, Inc was founded in 2016 and is based in San Diego, California.

Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.